Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solid Biosciences Inc.

www.solidbio.com

Latest From Solid Biosciences Inc.

Made In China Gene Therapy A Father's Quest To Save Son With UltraRare Condition

Patient-driven drug development meets the old saying of "where there's a will, there's a way" in China, potentially the world's largest market for rare disease treatments.

Gene Therapy Innovation

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies

Sarepta Shares Bounce As Pfizer’s DMD Gene Therapy Sparks Safety Concerns

Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.

Gene Therapy Rare Diseases

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Solid Ventures
  • Solid Biosciences LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Solid Biosciences Inc.
  • Senior Management
  • Ilan Ganot, CEO
    Jennifer Ziolkowski, CFO
    Carl Morris , PhD, CSO
    Joel Schneider, PhD, CTO, Head, Exploratory R&D
    Jorge A Quiroz, MD, CMO
    Alvaro Amorrortu, COO
  • Contact Info
  • Solid Biosciences Inc.
    Phone: (617) 337-4680
    161 First St.
    3rd Floor
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register